Vanguard Personalized Indexing Management LLC Has $1.08 Million Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Vanguard Personalized Indexing Management LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 20,711 shares of the biopharmaceutical company’s stock after acquiring an additional 2,463 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Halozyme Therapeutics were worth $1,084,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. TD Asset Management Inc lifted its position in Halozyme Therapeutics by 517.0% in the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after purchasing an additional 1,662,390 shares during the period. Norges Bank bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth about $44,935,000. Epoch Investment Partners Inc. lifted its holdings in shares of Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock worth $42,986,000 after acquiring an additional 831,199 shares during the period. Boston Trust Walden Corp acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $23,211,000. Finally, Swedbank AB bought a new stake in Halozyme Therapeutics in the first quarter valued at about $13,927,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on HALO. TD Cowen lifted their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. Piper Sandler cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $48.00 to $51.00 in a research report on Friday, June 7th. Finally, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Halozyme Therapeutics Price Performance

Shares of HALO stock opened at $58.53 on Tuesday. Halozyme Therapeutics, Inc. has a 1 year low of $32.83 and a 1 year high of $65.53. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The firm’s 50 day moving average is $58.52 and its 200-day moving average is $49.37. The firm has a market capitalization of $7.45 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 0.57 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.18. The firm had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction dated Monday, July 22nd. The shares were sold at an average price of $53.93, for a total transaction of $269,650.00. Following the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $834,836.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 5,000 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total transaction of $269,650.00. Following the completion of the sale, the chief financial officer now owns 15,480 shares in the company, valued at approximately $834,836.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at $10,778,084.68. The disclosure for this sale can be found here. Insiders sold a total of 84,881 shares of company stock worth $4,888,184 over the last three months. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.